PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1530758
PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1530758
According to Stratistics MRC, the Global Vitamin K2 Market is accounted for $159.6 million in 2024 and is expected to reach $574.7 million by 2030 growing at a CAGR of 23.8% during the forecast period. Vitamin K2 is a fat-soluble vitamin essential for blood clotting and bone metabolism. It plays a crucial role in activating proteins that regulate calcium distribution, directing it to bones and teeth while preventing arterial calcification. K2 supports cardiovascular health, bone strength, and dental health. They are found in fermented foods and animal products and are also available as supplements. The potential benefits for cognitive function and insulin sensitivity make it increasingly popular in health-conscious circles.
Growing health consciousness
Growing health consciousness drives the vitamin K2 market as consumers increasingly prioritize preventive healthcare and nutritional supplements. Vitamin K2 is recognized for its role in bone health, cardiovascular health, and potentially in other physiological functions. Rising awareness about the benefits of Vitamin K2 among health-conscious individuals and proactive healthcare initiatives contribute to market growth, fostering demand for supplements and fortified foods containing Vitamin K2.
Limited consumer awareness
Despite growing interest, limited consumer awareness about vitamin K2 remains a significant restraint on market growth. Many people are unfamiliar with Vitamin K2's specific benefits and how it differs from Vitamin K1. This lack of knowledge can lead to confusion and hesitation when purchasing vitamin K2 products. Additionally, healthcare professionals may not consistently recommend vitamin K2 supplements due to limited familiarity.
Aging population
Technological advancements in sensor technology present significant opportunities for the Vitamin K2 market. Innovations such as wireless sensor networks, advanced pH, turbidity, and dissolved oxygen sensors enhance the accuracy and efficiency of Vitamin K2. These advancements enable real-time data collection and analysis, improving contamination detection and water quality management, thus driving market growth.
Competition from other vitamins
Competition from other vitamins poses a significant threat to the vitamin K2 market. More established and well-known vitamins like vitamin D and calcium often overshadow vitamin K2 in the bone health segment. Consumers may prioritize these familiar nutrients over vitamin K2. Additionally, multivitamin formulations that claim to provide comprehensive nutrition can reduce the perceived need for standalone vitamin K2 supplements.
The COVID-19 pandemic initially disrupted the Vitamin K2 market through supply chain interruptions and reduced production. However, it also increased consumer focus on preventive health measures and immune support. This led to growing interest in vitamins and supplements, including Vitamin K2. The pandemic highlighted the importance of overall health and nutrition, potentially driving long-term growth in the Vitamin K2 market as consumers prioritize wellness.
The MK-7 segment is expected to be the largest during the forecast period
The MK-7 segment is anticipated to dominate the vitamin K2 market due to its superior bioavailability and longer half-life compared to other forms. MK-7 remains active in the body for a longer duration, providing sustained benefits. Its effectiveness in lower doses makes it attractive for supplement formulations. The growing body of research supporting MK-7's benefits for bone and cardiovascular health contributes to its market dominance. Consumers and manufacturers increasingly prefer the MK-7 for its proven efficacy, driving its larger market share.
The synthetic segment is expected to have the highest CAGR during the forecast period
The synthetic vitamin K2 segment is projected to experience the highest growth rate due to several factors. Synthetic production methods offer consistent quality, scalability, and cost-effectiveness compared to natural sources. This allows manufacturers to meet increasing demand while maintaining product stability. Synthetic vitamin K2 can be produced year-round, independent of natural source limitations. Advancements in production technologies are improving the purity and bioavailability of synthetic forms, making them increasingly comparable to natural sources. These factors contribute to the rapid growth of the synthetic segment.
Asia Pacific is poised to dominate the vitamin K2 market due to several factors. The region's large population and increasing health awareness drive demand for nutritional supplements. Countries like Japan have a long history of vitamin K2 consumption through traditional foods like natto. Growing disposable incomes and urbanization in countries like China and India are fueling the wellness industry. The presence of major vitamin K2 manufacturers in the region, coupled with a strong nutraceutical market, contributes to Asia Pacific's market leadership. Additionally, government initiatives promoting preventive healthcare support market growth.
Asia Pacific is expected to maintain the highest growth rate in the vitamin K2 market. Rapid urbanization and changing lifestyles are increasing the prevalence of lifestyle-related health issues, driving demand for preventive supplements. The region's aging population, particularly in countries like Japan and South Korea, creates a growing market for bone and cardiovascular health products. Increasing consumer education about nutrition and wellness is boosting vitamin K2 awareness. The expanding middle class and rising healthcare expenditure in emerging economies contribute to the region's high growth rate in the vitamin K2 market.
Key players in the market
Some of the key players in Vitamin K2 market include Kappa Bioscience, Lesaffre, DSM Nutritional Products, NattoPharma, Kyowa Hakko Bio Co., Ltd., Viridis BioPharma, Seebio Biotech (Shanghai) Co., Ltd., Danisco A/S, Frutarom, Shandong Guangtongbao Pharmaceuticals Co., Ltd., GeneFerm Biotechnology Co., Ltd., Penglai Marine Bio-Tech Co., Ltd., Herbonutra, J-Oil Mills, Inc., Zhejiang Hisun Bio-Tech Co., Ltd., Yihai Kerry Group, Huazhong Pharmaceutical Co., Ltd. and NattoPharma ASA.
In March 2024, Kyowa Hakko Bio, Co., Ltd. and Kyowa Hakko USA, Inc., a subsidiary of Kirin Holdings Co., has opened its expanded citicoline manufacturing facility at its Kyowa Hakko Bio Yamaguchi Production Center in Hofu City, Yamaguchi Prefecture, Japan. With the expanded facility, the Kirin Group is planning to integrate citicoline into upcoming product development initiatives, the company said. Kyowa Hakko Bio manufactures Cognizin, a citicoline brand, through a fermentation process for health food and pharmaceutical manufacturers.
In November 2023, Lesaffre is expanding its footprint in the United States through several capital investments and acquisitions. The company, which primarily focuses on yeast, bacteria and baking ingredients, is expanding into the nutrition, health and biotechnology sectors. With the expansion, the company is investing in both new equipment and R&D. Lesaffre has added a 10th fermentor for the Red Star Yeast, LLC yeast plant in Cedar Rapids, Iowa. At the same plant, the company also invested in a new dryer for its Phileo, Lesaffre business unit focused on animal nutrition and health customer demand, the company said.
In June 2022, Fermenta Biotech and Kappa Bioscience, a Norwegian entity, have announced a strategic partnership that positions Fermenta as the distributor of Kappa's K2VITAL MCT and MCC range of vitamin K2 for the Indian market. The collaboration combines Kappa's vitamin K2 manufacturing capabilities with Fermenta's distribution network and market expertise in India.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.